SCHEMBL5887629

SCHEMBL5887629

Cc1ccc(C2=C(c3ccc(Cl)c(Cl)c3)C(Cl)=C(Cl)[CH]C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALKBH3 Q96Q83 1/20 0.46
AHR P35869 5/20 0.38
PTGS2 P35354 3/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
MAOB P27338 3/20 0.35
HPGD P15428 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP1B1 Q16678 1/20 0.34
EGFR P00533 2/20 0.34
SLC6A3 Q01959 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PGR P06401 1/20 0.33
PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887035 0.79 ALKBH3 (0.43) ALKBH3AHRPTGS2ESR1ESR2
SCHEMBL5887214 0.78 RAD51 (0.46) ALKBH3AHRESR1EGFRSLC6A3
SCHEMBL5887503 0.75 ALKBH3 (0.40) ALKBH3AHRPTGS2ESR1ESR2
SCHEMBL1047370 0.70 AHR (0.70) ALKBH3AHRMAOBHPGDCYP2D6
SCHEMBL5887126 0.70 ALKBH3 (0.42) ALKBH3AHRMAOBHPGDCYP2D6
SCHEMBL5886968 0.67 ALKBH3 (0.39) ALKBH3AHRMAOBHPGDCYP2D6
SCHEMBL12190129 0.64 AHR (0.59) ALKBH3AHRESR1ESR2HPGD
SCHEMBL5887212 0.64 ALKBH3 (0.39) ALKBH3AHRMAOBHPGDCYP2D6
SCHEMBL6047624 0.64 ESR1 (0.35) ESR1ESR2HPGDCYP2D6CYP2C9
SCHEMBL5887265 0.63 LTA4H (0.49) PTGS2ESR1MEN1KMT2APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ALKBH3 3753/4885AHR 16/4885PTGS2 2354/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ALKBH3 3208/4885AHR 28/4885PTGS2 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.